The hepatitis therapeutics market size has grown steadily in recent years. It will grow from $19.08 billion in 2025 to $19.78 billion in 2026 at a compound annual growth rate (CAGR) of 3.7%. The growth in the historic period can be attributed to high prevalence of hepatitis b and c infections, introduction of interferon-based therapies, expansion of public vaccination initiatives, increased blood screening and diagnostic awareness, government-led viral hepatitis control programs.
The hepatitis therapeutics market size is expected to see steady growth in the next few years. It will grow to $23.43 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to growing uptake of direct-acting antivirals, rising investment in novel immune modulators, improved access to treatment in emerging markets, increasing diagnosis rates through screening programs, pipeline development for pan-genotypic therapies. Major trends in the forecast period include rising adoption of direct-acting antivirals for hepatitis c, increasing focus on combination therapies for chronic hepatitis, expansion of vaccination programs for hepatitis prevention, shift toward oral antiviral-based long-term management, growing use of online and specialty pharmacies for drug access.
The increasing number of clinical trials is expected to drive the growth of the hepatitis therapeutics market in the coming years. Clinical trials are research studies conducted to evaluate new treatments, drugs, or interventions in human participants. They play a vital role in the development of hepatitis therapeutics by providing a rigorous and ethical framework to assess the safety and efficacy of potential treatments, ensuring patients have access to the most effective therapies. For example, in December 2024, the Association of the British Pharmaceutical Industry, a UK-based nonprofit organization, reported that industry-initiated clinical trials in the UK increased from 411 trials in 2022 to 426 trials in 2023, representing a 3.7% growth. Therefore, the rising number of clinical trials is fueling the expansion of the hepatitis therapeutics market.
Leading companies in the hepatitis therapeutics market are pursuing strategic agreements to develop new treatments and gain a competitive advantage. A strategic agreement is a formal contract between two or more parties that defines the terms of collaboration to achieve shared business objectives. For example, in October 2023, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology company, announced an agreement to obtain an exclusive license for JNJ-3989, an investigational subcutaneous RNA interference (RNAi) therapeutic for the treatment of chronic hepatitis B (CHB). JNJ-3989 is a novel RNAi therapy that targets the hepatitis B virus (HBV) X protein, which is critical for HBV replication and viral persistence.
In February 2024, Gilead Sciences Inc., a U.S.-based pharmaceutical company, acquired Cymabay Therapeutics, Inc., for an undisclosed amount. This acquisition allows Gilead to expand its liver disease portfolio by integrating seladelpar, an investigational therapy for primary biliary cholangitis (PBC), aimed at addressing unmet medical needs and improving treatment options for patients with chronic liver conditions. Cymabay Therapeutics, Inc., is a U.S.-based clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic diseases, particularly liver disorders and diabetes.
Major companies operating in the hepatitis therapeutics market are Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Biocon Biopharmaceuticals Pvt. Ltd.
North America was the largest region in the hepatitis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatitis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have created moderate challenges for the hepatitis therapeutics market by increasing costs for active pharmaceutical ingredients, formulation inputs, and finished antiviral drugs traded across borders. These cost pressures affect oral antivirals and immune modulators most significantly, with Asia-Pacific and emerging markets facing pricing and supply constraints due to import dependence. However, tariffs are also encouraging local manufacturing, regional supply chain diversification, and domestic API production, which may strengthen long-term market resilience and affordability.
The hepatitis therapeutics market research report is one of a series of new reports that provides hepatitis therapeutics market statistics, including hepatitis therapeutics industry global market size, regional shares, competitors with a hepatitis therapeutics market share, detailed hepatitis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis therapeutics industry. This hepatitis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hepatitis is an inflammation of the liver caused by viral or non-viral factors. Hepatitis therapeutics refers to the drugs used to treat various forms of hepatitis. The main classes of drugs used for treatment include immune modulators and oral antivirals.
Hepatitis therapeutics are used to treat disease types such as hepatitis A, hepatitis B, hepatitis C, and others. Hepatitis A is a form of liver inflammation that can range from mild to severe illness. These drugs are classified by drug class into oral antivirals and immune modulators and are distributed through hospital pharmacies, drug stores, retail pharmacies, and online providers.
The hepatitis therapeutics market consists of revenues earned by entities by providing services such as lifestyle modifications, nutritional support, and liver transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis therapeutics market also includes sales of corticosteroids, immune globulins, and Immune globulins which are used in providing hepatitis therapeutics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The hepatitis therapeutics market size is expected to see steady growth in the next few years. It will grow to $23.43 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to growing uptake of direct-acting antivirals, rising investment in novel immune modulators, improved access to treatment in emerging markets, increasing diagnosis rates through screening programs, pipeline development for pan-genotypic therapies. Major trends in the forecast period include rising adoption of direct-acting antivirals for hepatitis c, increasing focus on combination therapies for chronic hepatitis, expansion of vaccination programs for hepatitis prevention, shift toward oral antiviral-based long-term management, growing use of online and specialty pharmacies for drug access.
The increasing number of clinical trials is expected to drive the growth of the hepatitis therapeutics market in the coming years. Clinical trials are research studies conducted to evaluate new treatments, drugs, or interventions in human participants. They play a vital role in the development of hepatitis therapeutics by providing a rigorous and ethical framework to assess the safety and efficacy of potential treatments, ensuring patients have access to the most effective therapies. For example, in December 2024, the Association of the British Pharmaceutical Industry, a UK-based nonprofit organization, reported that industry-initiated clinical trials in the UK increased from 411 trials in 2022 to 426 trials in 2023, representing a 3.7% growth. Therefore, the rising number of clinical trials is fueling the expansion of the hepatitis therapeutics market.
Leading companies in the hepatitis therapeutics market are pursuing strategic agreements to develop new treatments and gain a competitive advantage. A strategic agreement is a formal contract between two or more parties that defines the terms of collaboration to achieve shared business objectives. For example, in October 2023, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology company, announced an agreement to obtain an exclusive license for JNJ-3989, an investigational subcutaneous RNA interference (RNAi) therapeutic for the treatment of chronic hepatitis B (CHB). JNJ-3989 is a novel RNAi therapy that targets the hepatitis B virus (HBV) X protein, which is critical for HBV replication and viral persistence.
In February 2024, Gilead Sciences Inc., a U.S.-based pharmaceutical company, acquired Cymabay Therapeutics, Inc., for an undisclosed amount. This acquisition allows Gilead to expand its liver disease portfolio by integrating seladelpar, an investigational therapy for primary biliary cholangitis (PBC), aimed at addressing unmet medical needs and improving treatment options for patients with chronic liver conditions. Cymabay Therapeutics, Inc., is a U.S.-based clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic diseases, particularly liver disorders and diabetes.
Major companies operating in the hepatitis therapeutics market are Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Biocon Biopharmaceuticals Pvt. Ltd.
North America was the largest region in the hepatitis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatitis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have created moderate challenges for the hepatitis therapeutics market by increasing costs for active pharmaceutical ingredients, formulation inputs, and finished antiviral drugs traded across borders. These cost pressures affect oral antivirals and immune modulators most significantly, with Asia-Pacific and emerging markets facing pricing and supply constraints due to import dependence. However, tariffs are also encouraging local manufacturing, regional supply chain diversification, and domestic API production, which may strengthen long-term market resilience and affordability.
The hepatitis therapeutics market research report is one of a series of new reports that provides hepatitis therapeutics market statistics, including hepatitis therapeutics industry global market size, regional shares, competitors with a hepatitis therapeutics market share, detailed hepatitis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis therapeutics industry. This hepatitis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hepatitis is an inflammation of the liver caused by viral or non-viral factors. Hepatitis therapeutics refers to the drugs used to treat various forms of hepatitis. The main classes of drugs used for treatment include immune modulators and oral antivirals.
Hepatitis therapeutics are used to treat disease types such as hepatitis A, hepatitis B, hepatitis C, and others. Hepatitis A is a form of liver inflammation that can range from mild to severe illness. These drugs are classified by drug class into oral antivirals and immune modulators and are distributed through hospital pharmacies, drug stores, retail pharmacies, and online providers.
The hepatitis therapeutics market consists of revenues earned by entities by providing services such as lifestyle modifications, nutritional support, and liver transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis therapeutics market also includes sales of corticosteroids, immune globulins, and Immune globulins which are used in providing hepatitis therapeutics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Hepatitis Therapeutics Market Characteristics
3. Hepatitis Therapeutics Market Supply Chain Analysis
4. Global Hepatitis Therapeutics Market Trends and Strategies
5. Hepatitis Therapeutics Market Analysis of End Use Industries
7. Global Hepatitis Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Hepatitis Therapeutics Total Addressable Market (TAM) Analysis for the Market
9. Hepatitis Therapeutics Market Segmentation
10. Hepatitis Therapeutics Market Regional and Country Analysis
11. Asia-Pacific Hepatitis Therapeutics Market
12. China Hepatitis Therapeutics Market
13. India Hepatitis Therapeutics Market
14. Japan Hepatitis Therapeutics Market
15. Australia Hepatitis Therapeutics Market
16. Indonesia Hepatitis Therapeutics Market
17. South Korea Hepatitis Therapeutics Market
18. Taiwan Hepatitis Therapeutics Market
19. South East Asia Hepatitis Therapeutics Market
20. Western Europe Hepatitis Therapeutics Market
21. UK Hepatitis Therapeutics Market
22. Germany Hepatitis Therapeutics Market
23. France Hepatitis Therapeutics Market
24. Italy Hepatitis Therapeutics Market
25. Spain Hepatitis Therapeutics Market
26. Eastern Europe Hepatitis Therapeutics Market
27. Russia Hepatitis Therapeutics Market
28. North America Hepatitis Therapeutics Market
29. USA Hepatitis Therapeutics Market
30. Canada Hepatitis Therapeutics Market
31. South America Hepatitis Therapeutics Market
32. Brazil Hepatitis Therapeutics Market
33. Middle East Hepatitis Therapeutics Market
34. Africa Hepatitis Therapeutics Market
36. Hepatitis Therapeutics Market Competitive Landscape and Company Profiles
37. Hepatitis Therapeutics Market Other Major and Innovative Companies
40. Hepatitis Therapeutics Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Hepatitis Therapeutics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses hepatitis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hepatitis therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hepatitis therapeutics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types2) By Drug Class: Oral Antivirals; Immune Modulators
3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers
Subsegments:
1) By Hepatitis A: Vaccines; Post-Exposure Prophylaxis (PEP)2) By Hepatitis B: Antiviral Medications; Immune Modulators; Vaccines
3) By Hepatitis C: Direct-Acting Antivirals (DAAs); Ribavirin; Interferon-Based Therapies
4) By Other Disease Types: Hepatitis D; Hepatitis E
Companies Mentioned: Gilead Sciences Inc.; Bristol-Myers Squibb Co.; AbbVie Inc.; Merck & Co. Inc.; Johnson & Johnson Services Inc.; Cipla Inc.; F Hoffmann-La Roche Ltd.; Biocon Limited; LAURUS Labs Ltd.; Zydus Lifesciences Limited; Hetero Healthcare Limited; Novartis AG; Sanofi SA; GlaxoSmithKline plc; Lupin Ltd.; Teva Pharmaceutical Industries Ltd.; NATCO Pharma Limited; Pfizer Inc.; AstraZeneca plc; Boehringer Ingelheim International GmbH; Biocon Biopharmaceuticals Pvt. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Hepatitis Therapeutics market report include:- Gilead Sciences Inc.
- Bristol-Myers Squibb Co.
- AbbVie Inc.
- Merck & Co. Inc.
- Johnson & Johnson Services Inc.
- Cipla Inc.
- F Hoffmann-La Roche Ltd.
- Biocon Limited
- LAURUS Labs Ltd.
- Zydus Lifesciences Limited
- Hetero Healthcare Limited
- Novartis AG
- Sanofi SA
- GlaxoSmithKline plc
- Lupin Ltd.
- Teva Pharmaceutical Industries Ltd.
- NATCO Pharma Limited
- Pfizer Inc.
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Biocon Biopharmaceuticals Pvt. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 19.78 Billion |
| Forecasted Market Value ( USD | $ 23.43 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
